

Anti-Anginal Drugs

Objectives:

- ❖ Recognize variables contributing to a balanced myocardial supply versus demand
- ❖ Expand on the drugs used to alleviate acute anginal attacks versus those meant for prophylaxis & improvement of survival
- ❖ Detail the pharmacology of nitrates, other vasodilators, and
- ❖ other drugs used as antianginal therapy



Special thanks to
436's
Pharmacology
Team!


Introduction

Signs and Symptoms of Angina Pectoris:

A clinical syndrome of chest pain (varying in severity) caused by ischemia of heart muscle. (the pain can radiate to left shoulder and arm)

Pain due to either obstruction or spasm of coronary artery.

Pain due to the accumulation of metabolites (K⁺, PGs, kinins, adenosine) secondary to ischemia




Coronary Arteries in Exercise

- During exercise respiration in skeletal muscles increase → the demand for O₂ & glucose also increases which means Cardiac Output must increase.
- Greater amount of blood to be delivered to skeletal muscle so we need perfusion to increase, therefore we need to increase the amount of blood that goes into the heart and increase the cardiac output.


What is the mechanism of Angina Pectoris?

Is a consequence of myocardial oxygen demand exceeding myocardial oxygen supply (that means that the blood supply of oxygen is less than what body needs) (obstruction lead to ischemia).


There is an imbalance between oxygen demand and oxygen supply



Determinants of Oxygen Demand & Supply




Types of Angina Pectoris




Cont.

What are the determinants of oxygen demand?



What are the determinants of oxygen supply?



Treatment of Angina

1. Agents that improve symptoms & ischemia

Traditional Approach

- Nitrates
- Beta Blocker
- Calcium Channel Blocker (CCB)

New Approaches

- Metabolic Modulation, eg. **Trimetazidine**
- Potassium channels openers, eg. **Nicorandil**
- Late Na⁺ current inhibition, eg. **Ranolazine**.
- Sinus Node inhibition, eg. **Ivabradine**



2. Agents that improve prognosis

Halt progression, prevent acute insult, improve survival.

Aspirin /
other
antiplatelet
agents

Statins



ACE
inhibitors

β -blockers

Organic Nitrates

Classification	Long acting	Short acting
Drug	<ul style="list-style-type: none"> ● Isosorbide mononitrate ● Isosorbide dinitrate 	<ul style="list-style-type: none"> ● Nitroglycerin (GTN) or glyceride dinitrate
Preparations	<ul style="list-style-type: none"> ● Isosorbide mononitrate -Oral sustained release ● Isosorbide Dinitrate -Sublingual tablets (fastest onset of action) -Oral sustained (extended) release (delayed onset, longer duration) -Infusion Preparations 	<ul style="list-style-type: none"> -Sublingual tablets -Spray -Transdermal patch -Oral or buccal (between cheek and teeth) sustained release chronic or nocturnal angina -I.V. Preparations
P.K.	<ul style="list-style-type: none"> -Oral isosorbide -Very well absorbed & 100% bioavailability -The <u>dinitrate</u> undergoes <u>denitration</u> to two <u>mononitrates</u> → both possess antianginal activity (mono and dinitrate both work) -(t_{1/2}: 1-3 hours) -Further <u>denitrated</u> metabolites conjugate to <u>glucuronic acid</u> in liver. -Excreted in urine. <div data-bbox="475 1363 808 1663" data-label="Figure"> </div>	<ul style="list-style-type: none"> -Significant (high) first pass metabolism occurs in the liver (10-20%) low bioavailability So giving it orally is not first choice -Given sublingual or via transdermal patch, or parenteral (routes of administration which bypass portal circulation) <div data-bbox="953 1286 1393 1663" data-label="Figure"> </div>
MOA	<p>By enzymes: Organic nitrate is reduced into nitrite into nitrosothiol which will release nitric oxide.</p> <p>Nitric oxide binds to guanylate cyclase in vascular smooth muscle cell to form cGMP. cGMP activates PKG to produce relaxation.</p> <p>Difference between organic nitrates and sodium nitroprusside: nitroprusside doesn't need enzymes to release Nitric oxide. (spontaneously)</p>	<div data-bbox="953 1680 1425 2047" data-label="Diagram"> </div>

Organic Nitrates Cont.

Classification	Long acting	Short acting
<p>Hemodynamic effects</p>	<ul style="list-style-type: none"> • <u>Venous</u> vasodilation (Decrease the preload) and decrease diastolic pressure • <u>Coronary</u> vasodilation (Increase the myocardial perfusion) • <u>Arterial</u> vasodilation (decrease afterload) • <u>Shunting (diverting)</u> of flow from normal area to ischemic area by <u>dilating collateral vessels</u> <div style="display: flex; justify-content: space-around; align-items: center;">   </div>	
<p>Indications</p>	<p>In stable angina:</p> <ul style="list-style-type: none"> -Prevention: <u>Persistent</u> prophylaxis for chronic or nocturnal angina (most likely he will use transdermal patch preparation) -<u>Congestive</u> Heart Failure: Second line treatment is isosorbide mononitrate + hydralazine (When there is ACE inhibitor contraindications) 	<p>In stable angina:</p> <ul style="list-style-type: none"> -Acute symptom relief (sublingual/spray) - <u>Situational</u> prophylaxis: sublingual for example before climbing mountain, before doing عمرة before physical stress -IN VARIANT ANGINA (sublingual) -IN UNSTABLE ANGINA (IV) -<u>Acute</u> Heart Failure -Refractory AHF, and AMI (IV)
<p>ADRs (Mostly due to vasodilation)</p>	<ul style="list-style-type: none"> -Throbbing headache -Flushing in blush area -Postural hypotension, dizziness & syncope -Tachycardia & palpitation -Rarely Methemoglobinemia (iron is in ferric state instead of ferrous, hemoglobin is unable to carry oxygen.) 	

Organic Nitrates Cont.

Classification	Long acting	Short acting
contraindications	<ul style="list-style-type: none"> • Known sensitivity to organic nitrates • Glaucoma: nitrates increase synthesis of aqueous humor formation • Head trauma or cerebral haemorrhage = Increase intracranial pressure. • Uncorrected hypovolemia • Concomitant administration of PDE5 Inhibitors (phosphodiesterase type 5 inhibitor)(Sildenafil this is viagra) why? because the nitrate and sildenafil will have a synergistic effect on CGMP and cause severe hypotension • Sildenafil + nitrates = severe hypotension & death 	
tolerance	<ul style="list-style-type: none"> • Loss of vasodilator response of nitrates on use of long-acting preparations (oral, transdermal) or continuous intravenous infusions, for more than a few hours without interruption. If tolerance occurs the patient will start feeling the pain again. • The Mechanism: <ol style="list-style-type: none"> 1-Compensatory neurohormonal counter-regulation (body response which causes vasoconstriction) 2-Depletion of free-SH (sulfahydrate) groups which is required for activation of nitrates. To decrease tolerance, the patient can take the drug but with a drug free period. <ul style="list-style-type: none"> • Nitrate tolerance can be overcome by: Smaller doses at increasing intervals (Nitrate free periods twice a day). Giving drugs that maintain tissue SH group e.g.Captopril. 	

Effects of nitrates in treatment of angina and their results

Effects	Results
↓ Arterial pressure	↓ O2 demand "By decreasing the afterload"
Reflex ↑ in contractility	↑ O2 demand "due stimulation of sympathetic activity after high dose which dilate arteries"
↑ Collateral flow	Improved perfusion to ischemic myocardium
↓ Ventricular volume	↓ O2 demand "By decreasing the preload"
Reflex tachycardia	↑ O2 demand "due stimulation of sympathetic activity after high dose which dilate arteries"
↓ Left ventricular diastolic pressure	Improve subendocardial perfusion
↓ Diastolic perfusion time due to tachycardia	↓ myocardial perfusion
Vasodilation of epicardial coronary arteries	Relief of coronary artery spasm

Some explanation

Mechanisms of Clinical Effect
 The beneficial and deleterious effects of nitrate-induced vasodilation are summarized in Table 12-2.

TABLE 12-2 Beneficial and deleterious effects of nitrates in the treatment of angina.


Effect	Mechanism and Result
Potential beneficial effects	
Decreased ventricular volume	Decreased work and myocardial oxygen requirement
Decreased arterial pressure	
Decreased ejection time	
Vasodilation of epicardial coronary arteries	Relief of coronary artery spasm
Increased collateral flow	Improved perfusion of ischemic myocardium
Decreased left ventricular diastolic pressure	Improved subendocardial perfusion
Potential deleterious effects	
Reflex tachycardia	Increased myocardial oxygen requirement; decreased diastolic perfusion time and coronary perfusion
Reflex increase in contractility	

Calcium Channel Blockers

Drug:	Classifications:	Selectivity:
Mechanism:	Dihydropyridines: <ul style="list-style-type: none"> ● Nifedipine, Nicardipine (<u>short acting</u>) ● Amlodipine (<u>long acting</u>) 	Nifedipine: Vascular smooth muscle
Antianginal actions:	Phenylalkylamines e.g. Verapamil	Cardiomyocytes
Therapeutic uses:	Benzthiazepines e.g. Diltiazem	Intermediate ON BOTH BUT NOT AS STRONG AS THE PREVIOUS
Mechanism:	<ul style="list-style-type: none"> ● Binding of calcium channel blockers [CCBs] to the L-type Ca channels (most important in the heart) ↓ their frequency of opening in response to depolarization ● ↓ entry of Ca → ↓ Ca release from internal stores (sarcoplasmic reticulum) → No Stimulus-Contraction Coupling → RELAXATION 	
Antianginal actions:	↓ Cardiomyocyte Contraction → ↓ cardiac work through their -ve inotropic & chronotropic action (verapamil strongest & diltiazem) → ↓ myocardial oxygen demand	
Therapeutic uses:	↓ VSMC Contraction → ↓ Afterload → ↓ cardiac work → ↓ myocardial oxygen demand	
Therapeutic uses:	Coronary dilatation → ↑ myocardial oxygen supply	
Therapeutic uses:	<ul style="list-style-type: none"> ● In variant (vasospastic) angina: → Attacks prevented (>60%) / sometimes variably aborted ● In unstable angina: Seldom (rarely) added in refractory cases. ● In stable angina: useful regular <u>prophylaxis</u> if with CHF 	

Calcium Channel Blockers

M.O.A



- Short acting dihydropyridine should be avoided?
- Yes, it can precipitate anginal attack and cause reflex tachycardia
- Can be combined to β -AR blockers?
- Yes, we can use dihydropyridine. But we can not combine Phenylalkylamines such as Verapamil which work on the heart because beta blocker works on the heart also but we can give something that works on the blood vessel like dihydropyridines.
- Can be combined with nitrates?
- Yes, because nitrates can cause reflex tachycardia and CCB like verapamil will decrease it.
- Dihydropyridines useful antianginal if with CHF?
- Yes, especially dihydropyridine which **reduce the preload and the afterload** by vasodilation and thus decreasing the workload of the heart and decrease in demand.

β Adrenergic Blockers

Type:

Selective β1 blocker

Examples:

Atenolol, Bisoprolol, Metoprolol

Antianginal Mechanism:

Decrease heart rate & contractility thus:

- Increase duration of diastole > increase coronary blood flow > **increase oxygen supply**
- Decrease workload > Decrease O2 consumption > Decrease oxygen demand

Indications in angina:

Stable

- Regular prophylaxis, selective are preferred.
(Because we don't want to block B2)
- First choice for chronic use.
- Can be combined with nitrates.
- **Can be combined with dihydropyridine CCB.** But not with verapamil.

Variant

Contraindicated

Unstable

Halts progression to MI, improve survival

Myocardial infarction

Reduce infarct size Reduce morbidity & mortality
→ reduce O2 demand
→ reduce arrhythmias

- b- blockers should be withdrawn gradually?
- Because of the upregulation of the receptors, if not withdrawn gradually severe tachycardia could occur.
- Given to diabetics with ischemic heart disease?
-With caution can be given because it interferes with insulin release and covers the symptoms of hypoglycemic state.

- In stable angina
cardioselective b-blockers are preferred.
Prolong use reduces incidence of sudden death.

- In Unstable angina
Halts progression to AMI, improve survival

- In Variant Angina
contraindicated

- IN AMI
Reduce infarct size, reduce morbidity and mortality

Potassium Channel Openers


Drug	Nicorandil
MOA	has dual mechanism of action : 1.Opens potassium K-ATP channels(arteriolar dilator) 2.NO donor as it has a nitrate moiety (venular dilator)
P.K	<ul style="list-style-type: none"> ● As K channel opener 1. On vascular smooth muscles: opening K channels > hyperpolarization > vasodilation. 2. On cardiomyocytes: opening K channels > repolarization > decrease cardiac work. ● As NO donor Increase in cGMP/PKG which leads to vasodilation.
Indication	-Prophylactic 2nd line therapy in stable angina -Refractory variant angina
ADRs	-Flushing -Headache -Hypotension -Palpitation -Weakness -Mouth & peri-anal ulcers -nausea and vomiting.

Metabolically Acting Agents




Drug	Trimetazidine Trimetazidine= Triacylglycerol(FA)	Ranolazine	Ivabradine
P.K.	<p>Oxygen requirement of glucose pathway is lower than Free Fatty Acids (FFA), so during ischemia oxidized FFA levels rise=blunting the glucose pathway = reduces oxygen demand without altering hemodynamics. no effect on pre or after load.</p>	<p>Inhibits late sodium current which increase during ischemia</p>	<p>-selectively blocks I_f, I_f current is an inward Na/K current that activates pacemaker cells of the SA node funny channel allow the passage of both Na and K. funny current = mixed Na/K current</p>
MOA	<p>shifts oxidation to glucose instead of FFA to reduce oxygen demand of heart.(save energy)</p>	<p>look at next slide.</p>	<p>↓ slope of depolarization, ↓ HR, ↓ myocardial work, ↓ oxygen demand.</p>
Indication	<p>add-on therapy. can't be used alone.</p>	<p>chronic angina patients concomitantly with other drugs</p>	<p>-Treatment of chronic stable angina in patients with normal sinus rhythm who can't take b-blockers. -in combination with b-blockers in heart failure with LVEF < 35% inadequately controlled by b-blocker alone and whose HR > 70/min</p>
ADRs	<p>GIT disturbances</p>	<p>dizziness,constipation</p>	<p>luminous phenomena</p>
Contra-indication	<p>-hypersensitivity - pregnancy & lactation</p>	<p>Prolongs QT intervals = contraindicated in class Ia & III antiarrhythmics -Toxicity develop due to interaction with CYT 450 inhibitor eg. diltiazem,verapamil, ketoconazole macrolideant</p>	<p>-</p>

Cont.



M.O.A of Trimetazidine



M.O.A of Ivabradine



M.O.A of Ranolazine



Helmi's Case

From
Pharmacology
Team 435

Helmi, a 62-year-old male smoker with Type 2 Diabetes Mellitus & hypertension presents with a 4-month history of exertional chest pain. Physical examination shows a BP of 152/90 mm Hg but is otherwise unremarkable. The ECG is normal, & laboratory tests show a fasting blood glucose value of 110 mg/dL, glycosylated hemoglobin 6.0%, creatinine 1.1 mg/dL, total cholesterol 160, LDL 120, HDL 38, & triglycerides 147 mg/dL. He exercises for 8 minutes, experiences chest pain, & is found to have a 2-mm ST-segment depression at the end of exercise.

1. Which signs or symptoms of Helmi suggest diagnosis of angina pectoris?

Exercise induce, chest pain and depression of ST segment*. *sign of ischemia

1. What life style modifications should Helmi carry out?

Quit smoking, control of diabetes, diet control and moderate exercise.

1. What triggers the onset of symptoms in helmi?

Exercise

1. What factors worsen the symptoms in case of Helmi?

Smoking, hypertension, diabetes and enhanced LDL.

1. What is the possible underlying cause of angina in Helmi?

Atherosclerotic plaque

1. If Helmi was prescribed nitrates & tolerance developed to its effect, how to overcome tolerance to nitrates?

Nitrate tolerance can be overcome by: Smaller doses at increasing intervals (Nitrate free periods twice a day) & Giving drugs that maintain tissue SH group e.g. Captoril.

1. Which antianginal drug is the best choice for the case of Helmi? And Why?

Nitroglycerine, if became tolerant to nitrates choose Ca channel blockers or beta blockers.

1. If Helmi dose not respond to monotherapy, what other drug should be added to his regimen?

Ca channel blockers (selective to blood vessels e.g. Amlodipine) + beta blockers

1. Which antihyperlipidemic drug should be prescribed to Helmi?

Statins, to decrease LDL levels.

Questions

MCQs:

1- A 52 year old man with stable Angina is participating in a race. Which of the following is the drug/administration method of choice:

- A) Isosorbide dinitrate, orally
- B) Isosorbide dinitrate, transdermal patch
- C) Nitroglycerin, subcutaneously
- D) Nitroglycerin, orally

2- Side effects of nitrates and nitrite drugs are, EXCEPT:

- A) Orthostatic hypotension
- B) Tachycardia and palpitation
- C) GI disturbance
- D) Throbbing Headache

3- A 47-year-old man recently diagnosed with stable angina started a treatment with sublingual nitroglycerin, as needed, and oral isosorbide mononitrate. Which of the following is a potential detrimental effect of nitrates in the prophylactic treatment of stable angina?

- A) Decreased ejection time
- B) Increased cardiac rate
- C) Increased capacitance of systemic veins
- D) Decreased arterial pressure

Questions

MCQs:

4- A 54-year-old man complained to his physician of palpitations, flushing of the face and vertigo. The man had been suffering for gastroesophageal reflux disease for three years. Two weeks ago he was diagnosed with exertional angina and started the prescribed therapy. Which of the following drugs most likely caused the patient's symptoms?

- A) Propranolol
- B) Verapamil
- C) Nifedipine
- D) Nitroglycerin

5- A 71-year-old man with congestive heart failure (treated with carvedilol) also suffers from angina. Which of the following is the drug of choice?

- A) Amlodipine
- B) Diltiazem
- C) Verapamil
- D) Nifedipine

6- Which of the following is contraindicated in variant angina?

- A) Nicorandil
- B) Nicardipine
- C) Metoprolol
- D) Verapamil

Questions

SAQ:


An 80-year-old woman suffers from stable angina and was prescribed medication. Name the drug and describe its hemodynamics:

Isosorbide mononitrate and dinitrate


- Venous vasodilation (Decrease the preload) and decrease diastolic pressure
- Coronary vasodilation (Increase the myocardial perfusion)
- Arterial vasodilation (decrease afterload)
- Shunting of flow from normal area to ischemic area by dilating collateral vessels

Name the metabolically acting agent used as add-on therapy to Nitrates, Calcium Channel Blockers, and β blockers and describe its pharmacological effect:

- 1) Trimetazidine.
- 2) Metabolism shifts during ischemia to FFA oxidation to provide more energy, but this requires more O₂. This drug shifts oxidation to glucose instead of FFA to reduce oxygen demand of heart.



“It is not hard, you just made it to the end!”



Team Leaders:

Hadeel Awartani

Yazeed Alharbi

Thanks for those who worked on this lecture:

Lujain Al-Zaid
Khloud Al-Wehaibi
Laila Al-Sabbagh
Rahaf Al-Thunayan
Majd Al-Barrak
Rawan Al-Tamimi
Sarah Al-Kathiri

Ghadah Al-Haidari
Alanoud Al-Mufarrej
Ghadah Al-Muhanna
Aljohara Al-Shunaifi
Maha Al-Amri
Dana Al-Kady
Sarah Al-Sultan

References:

✓ Doctors' notes and slides



@Pharma4370



pharmacology437@gmail.com